July 30, 2024

Since last month's announcement on the results from the Phase 3 CIFFREO study evaluating fordadistrogene movaparvovec, we have made the difficult decision to discontinue its development.

At this time we are focused on conducting a more detailed review of these data, which will be shared at future medical and patient advocacy forums. To ensure participant safety, all boys who received fordadistrogene movaparvovec in the clinical program will be followed up for long-term safety monitoring.

We are greatly saddened by the results, and the CIFFREO outcome is not what any of us hoped for. But we believe there will be much to learn from these findings and hope they can contribute to future research that could lead to future scientific breakthroughs for boys living with DMD.

We know how absolutely crucial it is to find transformative treatments for boys that are living with DMD and we want to again thank this incredible community – including but not limited to the participants who have enrolled in trials in the fordadistrogene movaparvovec program, their supportive families, and the trial investigators involved.

Sincerely,
The Pfizer DMD gene therapy team